How many stocks are there of Ergomed?
The current number of stocks of Ergomed is 51.29 M undefined.
Ergomed Stocks 2024
Ergomed Stocks
51.29 M
Ticker
ERGO.L
ISIN
GB00BN7ZCY67
WKN
A117XM
In 2024, Ergomed had 51.29 M outstanding stocks, a 0% change from the 51.29 M stocks in the previous year.
The Ergomed Stocks history
| YEAR | NUMBER OF STOCKS (undefined GBP) |
|---|---|
| 2030e | 51.29 |
| 2029e | 51.29 |
| 2028e | 51.29 |
| 2027e | 51.29 |
| 2026e | 51.29 |
| 2025e | 51.29 |
| 2024e | 51.29 |
| 2023e | 51.29 |
| 2022 | 51.29 |
| 2021 | 50.57 |
| 2020 | 50.5 |
| 2019 | 48.63 |
| 2018 | 44.69 |
| 2017 | 41.09 |
| 2016 | 35.57 |
| 2015 | 29.77 |
| 2014 | 25.07 |
| 2013 | 20.94 |
| 2012 | 28.75 |
| 2011 | 28.75 |
Ergomed shares outstanding GB00BN7ZCY67 · A117XM
The number of shares was Ergomed in 2023 — This indicates how many shares 51.291 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Ergomed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Ergomed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Ergomed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ergomed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 28.75 M Aktien |
| 2012 | 28.75 M Aktien |
| 2013 | 20.94 M Aktien |
| 2014 | 25.07 M Aktien |
| 2015 | 29.77 M Aktien |
| 2016 | 35.57 M Aktien |
| 2017 | 41.09 M Aktien |
| 2018 | 44.69 M Aktien |
| 2019 | 48.63 M Aktien |
| 2020 | 50.5 M Aktien |
| 2021 | 50.57 M Aktien |
| 2022 | 51.29 M Aktien |
| 2023e | 51.29 M Aktien |
| 2024e | 51.29 M Aktien |
| 2025e | 51.29 M Aktien |
| 2026e | 51.29 M Aktien |
| 2027e | 51.29 M Aktien |
| 2028e | 51.29 M Aktien |
| 2029e | 51.29 M Aktien |
| 2030e | 51.29 M Aktien |
Ergomed Aktienanalyse
What does Ergomed do?
Ergomed PLC is a company specialized in clinical research, based in the UK since 1997. It specializes in supporting biotech and pharmaceutical companies in conducting clinical phase studies and post-marketing surveillance. Ergomed is listed on the London Stock Exchange and has offices in Europe and the USA. The company was originally founded as Ergomed Clinical Research Limited by physician Miroslav Reljanovic, who recognized the lack of resources for small biotech companies to conduct their own clinical studies. Ergomed offers a range of services tailored to the needs of biotech and pharmaceutical companies, including clinical research services, medical information and pharmacovigilance services, and regulatory affairs. It also provides venture capital investments for selected biotech companies. Ergomed offers comprehensive clinical research services, including study planning, trial management, and study monitoring. It also has expertise in data management and statistics to ensure accurate results. The company provides medical information to inform patients and healthcare professionals and offers support for drug monitoring during and after approval. Ergomed also supports companies in submitting regulatory applications and addressing regulatory questions. It has extensive experience working with national, European, and global regulatory authorities to ensure drug approval and compliance. Ergomed does not offer its own products but provides services to biotech and pharmaceutical companies. It collaborates with various companies to conduct clinical trials and develop drugs. In conclusion, Ergomed is a specialized company in clinical research that offers a wide range of services to biotech and pharmaceutical companies. It specializes in supporting them in conducting clinical phase studies and post-marketing surveillance. Ergomed has extensive experience working with regulatory authorities at national, European, and global levels to ensure drug approval and compliance. Ergomed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Ergomed's Shares Outstanding
Ergomed's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Ergomed’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Ergomed’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Ergomed’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Ergomed stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Ergomed are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Ergomed evolved in recent years?
The number of shares of Ergomed has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Ergomed as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Ergomed?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Ergomed pay?
Over the past 12 months, Ergomed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ergomed is expected to pay a dividend of 0 GBP.
What is the dividend yield of Ergomed?
The current dividend yield of Ergomed is .
When does Ergomed pay dividends?
Ergomed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Ergomed?
Ergomed paid dividends every year for the past 0 years.
What is the dividend of Ergomed?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Ergomed located?
Ergomed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ergomed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ergomed from 8/28/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did Ergomed pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of Ergomed in the year 2023?
In the year 2023, Ergomed distributed 0 GBP as dividends.
In which currency does Ergomed pay out the dividend?
The dividends of Ergomed are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Ergomed stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Ergomed
Our stock analysis for Ergomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ergomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
